Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel BS Switzerland 4070
- IPO Date
- Aug 3, 2012
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company that discovers, develops, and markets innovative medicines and diagnostic tests. The company operates through two primary segments: Pharmaceuticals, which focuses on oncology, immunology, infectious diseases, ophthalmology, and neurology; and Diagnostics, which provides clinical chemistry, coagulation, and molecular diagnostics solutions. Its core products and services include pharmaceutical brands such as Tecentriq (atezolizumab) for cancer immunotherapy, Hemlibra (emicizumab) for hemophilia A, Ocrevus (ocrelizumab) for multiple sclerosis, Evrysdi (risdiplam) for spinal muscular atrophy, and Actemra/RoActemra (tocilizumab) for rheumatoid arthritis and cytokine release syndrome; diagnostic offerings encompass the cobas platform for in vitro diagnostics, including cobas pro integrated solutions, Accu-Chek for diabetes management, and Ventana for pathology testing. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland, with global operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East, serving healthcare professionals, patients, and research institutions. In recent developments, the company expanded its diagnostics portfolio through the 2024 launch of the cobas 5800 analyser system for high-volume clinical chemistry testing and strengthened its oncology pipeline via a strategic collaboration with Regeneron Pharmaceuticals announced in late 2024 to co-develop faricimab for additional indications; additionally, Roche completed the acquisition of Poseida Therapeutics in mid-2025 for $1.5 billion to bolster its cell therapy capabilities in hematology and solid tumors.
Company News
Roche signs global licensing pact for Simcere's experimental blood cancer drug
U.S.' 'win' in the war has been choking off Iran's oil exports: David Roche
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Roche Is Getting More Benefit Of The Doubt On Improving Execution
Roche launches two new cyclospora tests as US outbreak widens
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
Roche Backs Full-Year View as First-Half Sales Rise
Roche confirms full year targets as first-half sales fall
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip